Although chronic kidney diseases are, I think, unrelated to OSA,
there is maybe a fear among investors that, as Novo Nordisk is
becoming bigger and more and more profitable, it might be able
to muscle its way through studies and clinical trials whistle
minimising or silencing the negative news about Ozempic side effects.
GLP-1 and OSA, page-24
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$38.15 |
Change
0.070(0.18%) |
Mkt cap ! $23.30B | |||
| Open | High | Low | Value | Volume |
| $38.10 | $38.22 | $37.91 | $30.20M | 792.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | $38.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.15 | 2018 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |